🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06663566
Enrolling by invitation Observational

Application of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload

NCT06663566 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Observational
Started
2024-08-15
Last updated
2024-10-29

Condition(s) studied

Right Heart InsufficiencyTricuspid Regurgitation

Investigational drug(s) / intervention(s)

Diagnose the patients right heart function as well as right heart fibrosisDiagnose the patient's right heart function as well as right heart fibrosisDiagnose the patient's right heart function as well as right heart fibrosis

Diagnose the patients right heart function as well as right heart fibrosis: Diagnose the patients right heart function as well as right heart fibrosis

Diagnose the patient's right heart function as well as right heart fibrosis: Diagnose the patient\'s right heart function as well as right heart fibrosis

Diagnose the patient's right heart function as well as right heart fibrosis: Diagnose the patient\'s right heart function as well as right heart fibrosis

Study summary

\"Bicuspid aortic stenosis represents the most prevalent form of cardiac valve disease, primarily resulting from degenerative alterations and rheumatic conditions that disrupt mitral valve function. This dysfunction exacerbates the hemodynamic burden on the right heart, leading to secondary pulmonary hypertension-a condition uniquely predisposed to myocardial fibrosis. The role of right ventricular (RV) fibrosis in pulmonary hypertension induced by bicuspid aortic stenosis remains an area of active investigation. Modifications in the extracellular matrix collagen network may mitigate excessive dilation of the pressure-overloaded right ventricle; however, fibrosis concurrently compromises cardiac performance. An increasing body of experimental evidence indicates that fibrosis is pivotal in both the onset and progression of right ventricular dysfunction. In cases of secondary pulmonary hypertension, the right ventricle endures a posterior load approximately five times greater than normal, rendering these circumstances an excellent model for examining pressure loading effects on RV structure. Notably, severe RV fibrosis persists even after hemodynamic normalization following mitral valve repair; thus, preoperative evaluation of RV fibrosis is essential for optimizing patient outcomes in individuals with secondary pulmonary hypertension attributable to bicuspid aortic stenosis.

In recent years, myocardial nuclear imaging has gained prominence as a tool for assessing myocardial fibrosis. Initial studies investigated FAPI myocardial nuclear imaging\'s efficacy in evaluating left ventricular fibrosis among patients with aortic stenosis; subsequent research elucidated its correlation with sudden cardiac death risk in individuals suffering from obstructive hypertrophic cardiomyopathy.

The comprehension regarding how myocardial fibrosis impacts right ventricular function within patients experiencing pulmonary hypertension due to bicuspid aortic stenosis remains limited. The association between histological RV fibrosis and adverse prognostic indicators as well as outcomes related to right heart failure warrants further exploration.\"

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: Clinical diagnosis of Tricuspid valve insufficiency; must understand the purpose of the study and signed an informed consent form; Exclusion Criteria: Combined coronary artery stenosis; Combined with aortic aneurysm related diseases; Patients with congenital heart disease;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
FAPI Beijing Beijing Municipality

More Beijing Anzhen Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06663566 on ClinicalTrials.gov ↗ ← All trials in China